[{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","commit":"925a04b429","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a third batch of thirty approved products","file":"src/data/spikes/multiple-myeloma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Linvoseltamab\" }]"}]},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/multiple-myeloma.ts","type":"changed","fields":[{"field":"tldr","before":"\"Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.\"","after":"\"Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.\""}]},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","commit":"2997dc2520","date":"2026-09-08","author":"Jude Gomila","message":"Deep cancer spikes: DLBCL, multiple myeloma, Hodgkin lymphoma, sarcoma, neuroblastoma (135 new entities with structured outcomes, dosing, to","file":"src/data/spikes/multiple-myeloma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]